SCHEMBL6976084

SCHEMBL6976084

CC(C)(C)OC(=O)N1CCN(C2CC3CCC(C2)N3C=O)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
HPGD P15428 1/20 0.43
EPHX2 P34913 1/20 0.42
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RECQL P46063 1/20 0.41
EPHX1 P07099 1/20 0.41
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PREP P48147 2/20 0.40
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
GPR119 Q8TDV5 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2239454 0.84 CHRM2 (0.46) CHRM2CHRM1CHRM3HPGDEPHX2
SCHEMBL63877 0.83 USP2 (0.53) CHRM2CHRM1CHRM3HPGDEPHX2
SCHEMBL6971872 0.82 CHRM2 (0.51) CHRM2CHRM1CHRM3HPGDEPHX2
SCHEMBL6971592 0.82 ALDH1A1 (0.44) CHRM2CHRM1CHRM3HPGDEPHX2
SCHEMBL22556823 0.81 USP2 (0.45) CHRM2CHRM1CHRM3HPGDEPHX2
SCHEMBL18550789 0.81 CHRM2 (0.43) CHRM2CHRM1CHRM3HPGDEPHX2
SCHEMBL22556800 0.80 HPGD (0.44) CHRM2CHRM1CHRM3HPGDEPHX2
SCHEMBL27502263 0.80 HPGD (0.44) HPGDEPHX2USP2SMN1; SMN2RECQL
SCHEMBL22556801 0.80 HPGD (0.44) CHRM2CHRM1CHRM3HPGDEPHX2
SCHEMBL24764754 0.79 CHRM2 (0.58) CHRM2CHRM1CHRM3HPGDEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176445-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. 2003-09-18 US disclosed
EP-1106615-B1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER (US) 2003-03-05 EP disclosed
US-20020042421-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists OKUMURA YOSHIYUKI (JP) 2002-04-11 US disclosed
EP-1106615-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. (US) 2001-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176445-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists BDKRB1, BDKRB2, HRH4 CHRM2 676/4885CHRM1 307/4885CHRM3 509/4885
US-20020042421-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists BDKRB1, BDKRB2, HRH4 CHRM2 580/4885CHRM1 265/4885CHRM3 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.